Population Pharmacokinetics of Amikacin in Indian Pediatric Patients

REFERENCES

• G Beaucaire, O Leroy, C Beuscart, P Karp, C Chidiac, and M Caillaux. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J. Antimicrob. Chemother. 1991; 27 (C):91–103.
   PubMedGoogle Scholar
• RD Moore, CR Smith, and PS Lietman. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J. Infect. Dis. 1984; 149:443–448.
   PubMed Web of Science ®Google Scholar
• RD Moore, CR Smith, and Lietman Ps. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am. J. Med. 1984; 77:657–662.
   PubMed Web of Science ®Google Scholar
• G Jaresko, B Boucher, EJ Dole, EA Tolley, and TC Fabian. Risk of renal dysfunction in critically ill trauma patients receiving aminoglycosides. Clin. Pharmacol. 1989; 8:43–48.
   PubMedGoogle Scholar
• JP Langhendries, O Battisti, JM Bertrand, A Francois, J Darimont, S Ibrahim, PM Tulkens, A Bernard, JP Buchet, and E Scalais. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev. Pharmacol. Ther. 1993; 20:220–230.
   PubMedGoogle Scholar
• RD Moore, P Lietman, and CR Smith. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J.Infect.Dis. 1987; 155:93–99.
   PubMed Web of Science ®Google Scholar
• X Dawei, DP Nicolau, and CH Nightingale. Population pharmacokinetics of gentamicin in hospitalized patients receiving once daily dosing. Int J of Antimicrobial Agents. 2004; 23:291–295.
   PubMed Web of Science ®Google Scholar
• DJ Demczar, AN Nafziger, and JS Bertino. Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once daily aminoglycosides dosing. Antimicrobial Agents Chemotherp. 1999; 43:623–629.
   PubMedGoogle Scholar
• JH Botha, MH du Preez, and M Adhikar. Population pharmacokinetics of gentamicin in South African newborns. Eur J Clin Pharmacol. 2003; 59:755–759.
   PubMed Web of Science ®Google Scholar
• MC Rosario, AH Thomson, DI Jodrell, CA Sharp, and HL Elliott. Population pharmacokinetics of gentamicin in patients with cancer. Br J of Clin Pharmacol. 1998; 46:229–236.
   PubMed Web of Science ®Google Scholar
• M Lingvall, D Reith, and R Broadbent. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol. 2005; 59 (1):54–61.
   PubMed Web of Science ®Google Scholar
• S Romano, P Gonzalez, P Tejada, J Anton, JM Aguado, and JM Lanao. Influence of diagnostic and treatment factors in the population pharmacokinetics of gentamicin. J Clin Pharm Ther. 1998; 23:141–148.
   PubMed Web of Science ®Google Scholar
• JM Tréluyer, Y Merlé, S Tonnelier, E Rey, and G Pons. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother. May, 2002; 46 (5):1381–1387.
   PubMed Web of Science ®Google Scholar
• I Mathews, C Kirkpetric, and N Holford. Quantitative justification for target concentration intervention— Parameter variability and predictive performance using population pharmacokinetics models for aminoglycosides. British J of Clinical Pharmacol. 2003; 58 (1):8–19.
   Web of Science ®Google Scholar
• DP Nicolau, CD Freeman, PP Belliveau, CH Nightingale, JW Ross, and R Quintiliani. Experience with a once daily amino glycoside program administered to 2184 adult patients. Antimicrob Agents Chemother. 1995; 39:650–655.
   PubMed Web of Science ®Google Scholar
• Y Hashimoto, and LB Sheiner. Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm. 1991; 19:333–353.
   PubMedGoogle Scholar
• JL Steimer, F Mentre, and A Mallet. Population studies for evaluation of pharmacokinetic variability: Why? How? When? In: J Hirtz, eds. 2nd European Congress on Biopharmaceutics and Pharmacokinetics, Vol. 2: Experimental Pharmacokinetics, Paris: Lavoisier; 1996: 40–49.
   Google Scholar
• S Vozeh, PO Maitre, and DR Stanski. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm. 1990; 18:161–173.
   PubMedGoogle Scholar
• H Bartels, M Bohmer, and C Heierli. Serum creatinine determination without protein precipitation. Clin. Chem. Acta. 1972; 37:193–197.
   PubMed Web of Science ®Google Scholar
• E Warren, RJ Snyder, and JA WashingtonII. Four-hour microbiological assay of gentamicin in Serum. Antimicrobial Agents and Chemotherapy. Jan, 1972; 46–48.
   PubMed Web of Science ®Google Scholar
• WA Craig. Does the dose matter?. Clin. Infect. Dis. 2001; 33 (3):S233–S237.
   PubMedGoogle Scholar
• CF Kenyon, DC Knoppert, SK Lee, HM Vandenberghe, and GW Chance. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob. Agents Chemother. 1990; 34:265–268.
   PubMed Web of Science ®Google Scholar
• RD Moore, CR Smith, and PS Liteman. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am. J. Med. 1984; 77:657–662.
   PubMed Web of Science ®Google Scholar
• A Taddio. Is there evidence for routine therapeutic drug monitoring in paediatric patients? G Koren, and O Diav-Citrineds., Paediatric Pharmacology: Toward Evidence-Based Drug Therapy, vol. 6. London: Baillere Tindall; 1998: 353–376.
   Google Scholar
• F Bressolle, A Gouby, J-M Martinez, P Joubert, G Saissi, R Guillaud, and R Gomeni. Population pharmacokinetics of amikacin in critically ill patients. Antimicrobial Agents and Chemotherapy July, 1996; 1682–1689.
   PubMed Web of Science ®Google Scholar
• NI Bukhari, S Yousuf, M Jamshaid, and M Mustafa. Pharmacokinetics of amikacin in febrile neutropenic pediatric patients with acute lymphoblastic leukaemia. Turkish Journal of Cancer. 2001; 31 (3):
   Google Scholar
• S Romano, Fdez de, MM Gatta, MV Calvo, D Caballero, A Dominguez-Gil, and JM Lanao. Population pharmacokinetics of amikacin in patients with haematological malignancies. Journal of Antimicrobial Chemotherapy. 1999; 44:235–242.
   PubMed Web of Science ®Google Scholar
• M Tod, O Lortholary, D Seytre, R Semaoun, B Uzzan, LC Guillevin, P Casassus, and O Petitjean. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrobial Agents and Chemotherapy Apr, 1998; 42 (4):849–856.
   PubMed Web of Science ®Google Scholar
• PE Marik, I Havlik, FSE Monteagudo, and J Lipman. The pharmacokinetics of amikacin in critically ill adult and pediatric patients: Comparison of once- versus twice-daily dosing regimens. J. Antimicrob. Chemother. 1991; 27 (C):81–89.
   PubMedGoogle Scholar
• RL Davis, D Lehmann, CA Stidley, and J Neidhart. Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy. Antimicrobial Agents and Chemotherapy. 1991; 35:944–947.
   PubMed Web of Science ®Google Scholar
• JV Etzel, AN Nafziger, and JS Bertino. Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrobial Agents and Chemotherapy. 1992; 36:679–681.
   PubMed Web of Science ®Google Scholar